# Pathogenic cytokines in thrombotic microangiopathies: molecular insights and therapeutic targets

## TL;DR

This paper explores how harmful cytokines contribute to blood vessel damage in thrombotic microangiopathies and identifies potential treatment targets.

## Contribution

The paper provides molecular insights into the role of pro-inflammatory cytokines in various thrombotic microangiopathy subtypes.

## Key findings

- TNF-α, IL-6, and IL-1β promote endothelial dysfunction and microthrombi formation in TMAs.
- Cytokine-mediated inflammation is a common feature across TMA subtypes like HUS and TTP.
- Cytokines contribute to vascular damage through increased permeability and procoagulant changes.

## Abstract

Thrombotic microangiopathies (TMAs) are a heterogeneous group of disorders characterized by endothelial damage, microvascular thrombosis, thrombocytopenia, and microangiopathic hemolytic anemia. While the initiating triggers may differ—ranging from infections and autoimmune diseases to genetic complement dysregulation—a unifying pathophysiological feature is injury to the vascular endothelium. Recent advances have highlighted the critical role of pro-inflammatory cytokines in mediating endothelial dysfunction, contributing to both the initiation and propagation of thrombotic events in TMAs. Cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) have been implicated in promoting endothelial activation, increased permeability, leukocyte adhesion, and procoagulant changes. These effects contribute to the loss of vascular integrity and the formation of microthrombi. Moreover, cytokine-mediated inflammation appears to be a common feature across various TMA subtypes, including Shiga toxin-associated hemolytic uremic syndrome (HUS), atypical HUS, thrombotic thrombocytopenic purpura (TTP), and secondary TMAs. The intensity and profile of cytokine involvement may vary, but their pathological influence on endothelial health remains a shared mechanism.